{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T05:19:15Z","timestamp":1792819155008,"version":"4.5.0"},"reference-count":141,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,1,8]],"date-time":"2021-01-08T00:00:00Z","timestamp":1610064000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Nanoparticle-based anticancer medications were first approved for cancer treatment almost 2 decades ago. Patients benefit from these approaches because of the targeted-drug delivery and reduced toxicity, however, like other therapies, adverse reactions often limit their use. These reactions are linked to the interactions of nanoparticles with the immune system, including the activation of complement. This activation can cause well-characterized acute inflammatory reactions mediated by complement effectors. However, the long-term implications of chronic complement activation on the efficacy of drugs carried by nanoparticles remain obscured. The recent discovery of protumor roles of complement raises the possibility that nanoparticle-induced complement activation may actually reduce antitumor efficacy of drugs carried by nanoparticles. We discuss here the initial evidence supporting this notion. Better understanding of the complex interactions between nanoparticles, complement, and the tumor microenvironment appears to be critical for development of nanoparticle-based anticancer therapies that are safer and more efficacious.<\/jats:p>","DOI":"10.3389\/fimmu.2020.603039","type":"journal-article","created":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T23:22:11Z","timestamp":1610061731000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":121,"title":["Nanoparticle-Induced Complement Activation: Implications for Cancer Nanomedicine"],"prefix":"10.3389","volume":"11","author":[{"given":"Ninh M.","family":"La-Beck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md. Rakibul","family":"Islam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maciej M.","family":"Markiewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,1,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1021\/mp200394t","article-title":"Nanomedicine(s) under the microscope","volume":"8","author":"Duncan","year":"2011","journal-title":"Mol Pharmaceutics"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S1567-5769(02)00271-0","article-title":"Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications","volume":"3","author":"Maeda","year":"2003","journal-title":"Int Immunopharmacol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2012.10.002","article-title":"The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo","volume":"65","author":"Maeda","year":"2013","journal-title":"Adv Drug Delivery Rev"},{"key":"B4","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.addr.2012.09.037","article-title":"Liposomal drug delivery systems: from concept to clinical applications","volume":"65","author":"Allen","year":"2013","journal-title":"Adv Drug Delivery Rev"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.6b08244","article-title":"Mechanisms and Barriers in Cancer Nanomedicine: Addressing Challenges, Looking for Solutions","volume":"11","author":"Anchordoquy","year":"2017","journal-title":"ACS Nano"},{"key":"B6","volume-title":"Drugs@FDA: FDA-Approved Drugs","year":"2020"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S79089","article-title":"A tale of the two PEGylated liposomal doxorubicins","volume":"8","author":"Chou","year":"2015","journal-title":"Onco Targets Ther"},{"key":"B8","volume-title":"Myocet liposomal (previously Myocet)","year":"2020"},{"key":"B9","volume-title":"Assessment Report for Mepact","year":"2009"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-016-1958-5","article-title":"Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date","volume":"33","author":"Bobo","year":"2016","journal-title":"Pharm Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1080\/02656730802104757","article-title":"Clinical applications of magnetic nanoparticles for hyperthermia","volume":"24","author":"Thiesen","year":"2008","journal-title":"Int J Hyperthermia"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11121855","article-title":"Thirty Years of Cancer Nanomedicine: Success, Frustration, and Hope","volume":"11","author":"Salvioni","year":"2019","journal-title":"Cancers"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-019-0269-6","article-title":"Enhancing cancer immunotherapy with nanomedicine","volume":"20","author":"Irvine","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2019.09.017","article-title":"Clinical applications of nanomedicine in cancer therapy","volume":"25","author":"Norouzi","year":"2020","journal-title":"Drug Discovery Today"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11111783","article-title":"Targeting Integrins in Cancer Nanomedicine: Applications in Cancer Diagnosis and Therapy","volume":"11","author":"Wu","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s12272-020-01217-2","article-title":"Nanoconfinement-mediated cancer theranostics","volume":"43","author":"Kang","year":"2020","journal-title":"Arch Pharm Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1021\/mp800032f","article-title":"Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution","volume":"5","author":"Dobrovolskaia","year":"2008","journal-title":"Mol Pharm"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00416","article-title":"Nanoparticle Interactions with the Immune System: Clinical Implications for Liposome-Based Cancer Chemotherapy","volume":"8","author":"La-Beck","year":"2017","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1124\/jpet.113.208801","article-title":"Translational studies of phenotypic probes for the mononuclear phagocyte system and liposomal pharmacology","volume":"347","author":"Caron","year":"2013","journal-title":"J Pharmacol Exp Ther"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/0009-3084(86)90079-4","article-title":"Interactions of liposomes with serum proteins","volume":"40","author":"Bonte","year":"1986","journal-title":"Chem Phys Lipids"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.nano.2014.11.003","article-title":"Liposome-protein corona in a physiological environment: challenges and opportunities for targeted delivery of nanomedicines","volume":"11","author":"Caracciolo","year":"2015","journal-title":"Nanomed Nanotechnol Biol Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"81","DOI":"10.2217\/nnm.15.188","article-title":"The impact of nanoparticle protein corona on cytotoxicity, immunotoxicity and target drug delivery","volume":"11","author":"Corbo","year":"2016","journal-title":"Nanomed (Lond)"},{"key":"B23","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.smim.2017.10.001","article-title":"Formation of the Protein Corona: The Interface between Nanoparticles and the Immune System","volume":"34","author":"Barbero","year":"2017","journal-title":"Semin Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/0304-4157(92)90004-T","article-title":"Immunologic aspects of liposomes: presentation and processing of liposomal protein and phospholipid antigens","volume":"1113","author":"Alving","year":"1992","journal-title":"Biochim Biophys Acta"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.60.6.2438-2444.1992","article-title":"Adjuvant effects of liposomes containing lipid A: enhancement of liposomal antigen presentation and recruitment of macrophages","volume":"60","author":"Verma","year":"1992","journal-title":"Infect Immun"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1081\/LPR-120004790","article-title":"Role of complement activation in hypersensitivity reactions to doxil and hynic PEG liposomes: experimental and clinical studies","volume":"12","author":"Szebeni","year":"2002","journal-title":"J Liposome Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdg374","article-title":"Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions","volume":"14","author":"Chanan-Khan","year":"2003","journal-title":"Ann Oncol"},{"key":"B28","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.146.12.4234","article-title":"The role of surface charge in the activation of the classical and alternative pathways of complement by liposomes","volume":"146","author":"Chonn","year":"1991","journal-title":"J Immunol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/0005-2736(94)90231-3","article-title":"Liposome-complement interactions in rat serum: implications for liposome survival studies","volume":"1191","author":"Devine","year":"1994","journal-title":"Biochim Biophys Acta"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2006.10.017","article-title":"PEGylation of microspheres for therapeutic embolization: preparation, characterization and biological performance evaluation","volume":"28","author":"Madani","year":"2007","journal-title":"Biomaterials"},{"key":"B31","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.molimm.2005.02.006","article-title":"Complement activation and protein adsorption by carbon nanotubes","volume":"43","author":"Salvador-Morales","year":"2006","journal-title":"Mol Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1002\/jbm.820180902","article-title":"The activation of the complement system by polymer materials and their blood compatibility","volume":"18","author":"Sevast\u2019ianov","year":"1984","journal-title":"J BioMed Mater Res"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1166\/jnn.2008.090","article-title":"Effects of covalent functionalization on the biocompatibility characteristics of multi-walled carbon nanotubes","volume":"8","author":"Salvador-Morales","year":"2008","journal-title":"J Nanosci Nanotechnol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2008.05.020","article-title":"Complement activation by PEGylated single-walled carbon nanotubes is independent of C1q and alternative pathway turnover","volume":"45","author":"Hamad","year":"2008","journal-title":"Mol Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1021\/nn101990a","article-title":"Distinct polymer architecture mediates switching of complement activation pathways at the nanosphere-serum interface: implications for stealth nanoparticle engineering","volume":"4","author":"Hamad","year":"2010","journal-title":"ACS Nano"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1166\/jnn.2006.406","article-title":"Concentration dependent structural ordering of poloxamine 908 on polystyrene nanoparticles and their modulatory role on complement consumption","volume":"6","author":"Al-Hanbali","year":"2006","journal-title":"J\u00a0Nanosci Nanotechnol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamem.2008.01.006","article-title":"Electrostatic interactions and complement activation on the surface of phospholipid vesicle containing acidic lipids: effect of the structure of acidic groups","volume":"1778","author":"Sou","year":"2008","journal-title":"Biochim Biophys Acta"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0902214","article-title":"Curvature of synthetic and natural surfaces is an important target feature in classical pathway complement activation","volume":"184","author":"Pedersen","year":"2010","journal-title":"J Immunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/S0163-7827(03)00033-X","article-title":"Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties","volume":"42","author":"Moghimi","year":"2003","journal-title":"Prog Lipid Res"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-5793(97)01022-3","article-title":"A novel type of binding specificity to phospholipids for rat mannose-binding proteins isolated from serum and liver","volume":"414","author":"Kuroki","year":"1997","journal-title":"FEBS Lett"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/S0076-6879(03)73010-9","article-title":"The interaction of liposomes with the complement system: in vitro and in vivo assays","volume":"373","author":"Szebeni","year":"2003","journal-title":"Methods Enzymol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1997.37297203517.x","article-title":"Complement activation in vitro by the red cell substitute, liposome-encapsulated hemoglobin: mechanism of activation and inhibition by soluble complement receptor type 1","volume":"37","author":"Szebeni","year":"1997","journal-title":"Transfusion"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1021\/bi00832a038","article-title":"Antibody binding and complement fixation by a liposomal model membrane","volume":"8","author":"Alving","year":"1969","journal-title":"Biochemistry"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-7352-1_13","article-title":"Analysis of Complement Activation by Nanoparticles","volume":"1682","author":"Neun","year":"2018","journal-title":"Methods Mol Biol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.engreg.2020.06.001","article-title":"Engineering nanoparticles to overcome immunological barriers for enhanced drug delivery","volume":"1","author":"Malachowski","year":"2020","journal-title":"Engineered Regeneration"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2011.06.002","article-title":"Material properties in complement activation","volume":"63","author":"Moghimi","year":"2011","journal-title":"Adv Drug Delivery Rev"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/nnano.2016.269","article-title":"Complement proteins bind to nanoparticle protein corona and undergo dynamic exchange in vivo","volume":"12","author":"Chen","year":"2017","journal-title":"Nat Nanotechnol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00131","article-title":"Human Properdin Opsonizes Nanoparticles and Triggers a Potent Pro-inflammatory Response by Macrophages without Involving Complement Activation","volume":"9","author":"Kouser","year":"2018","journal-title":"Front Immunol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/nature05172","article-title":"Structure of C3b reveals conformational changes that underlie complement activity","volume":"444","author":"Janssen","year":"2006","journal-title":"Nature"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.actbio.2018.04.053","article-title":"Curvature-dependent effects of nanotopography on classical immune complement activation","volume":"74","author":"Westas Janco","year":"2018","journal-title":"Acta Biomater"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/nnano.2017.47","article-title":"Bypassing adverse injection reactions to nanoparticles through shape modification and attachment to erythrocytes","volume":"12","author":"Wibroe","year":"2017","journal-title":"Nat Nanotechnol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1080\/17435390.2017.1306131","article-title":"Non-specific adsorption of complement proteins affects complement activation pathways of gold nanomaterials","volume":"11","author":"Quach","year":"2017","journal-title":"Nanotoxicology"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1096\/fj.06-6186fje","article-title":"Methylation of the phosphate oxygen moiety of phospholipid-methoxy(polyethylene glycol) conjugate prevents PEGylated liposome-mediated complement activation and anaphylatoxin production","volume":"20","author":"Moghimi","year":"2006","journal-title":"FASEB J"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2013.05.030","article-title":"Complement monitoring of Pluronic 127 gel and micelles: suppression of copolymer-mediated complement activation by elevated serum levels of HDL, LDL, and apolipoproteins AI and B-100","volume":"170","author":"Hamad","year":"2013","journal-title":"J Control Release"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1039\/C5TB01825K","article-title":"Materials design at the interface of nanoparticles and innate immunity","volume":"4","author":"Szeto","year":"2016","journal-title":"J Mater Chem B"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M110.180760","article-title":"Variable antibody-dependent activation of complement by functionalized phospholipid nanoparticle surfaces","volume":"286","author":"Pham","year":"2011","journal-title":"J Biol Chem"},{"key":"B57","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/S0005-2736(99)00013-9","article-title":"C1q binding to liposomes is surface charge dependent and is inhibited by peptides consisting of residues 14-26 of the human C1qA chain in a sequence independent manner","volume":"1418","author":"Bradley","year":"1999","journal-title":"Biochim Biophys Acta"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v14.i2.10","article-title":"The role of immunoproteins in the survival of liposomes in the circulation","volume":"14","author":"Devine","year":"1997","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2013.12.085","article-title":"Mediation of a non-proteolytic activation of complement component C3 by phospholipid vesicles","volume":"35","author":"Klapper","year":"2014","journal-title":"Biomaterials"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1002\/jbm.a.30711","article-title":"Evaluation of pegylated lipid nanocapsules versus complement system activation and macrophage uptake","volume":"78","author":"Vonarbourg","year":"2006","journal-title":"J BioMed Mater Res A"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2010.11.037","article-title":"Engineering complement activation on polypropylene sulfide vaccine nanoparticles","volume":"32","author":"Thomas","year":"2011","journal-title":"Biomaterials"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S161369","article-title":"Involvement of complement activation in the pulmonary vasoactivity of polystyrene nanoparticles in pigs: unique surface properties underlying alternative pathway activation and instant opsonization","volume":"13","author":"Meszaros","year":"2018","journal-title":"Int J Nanomed"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.01.024","article-title":"Polyplex Evolution: Understanding Biology","volume":"25","author":"Hall","year":"2017","journal-title":"Optimizing Performance Mol Ther"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1007\/s10544-009-9336-2","article-title":"Influence of PEG chain on the complement activation suppression and longevity in vivo prolongation of the PCL biomedical nanoparticles","volume":"11","author":"Shan","year":"2009","journal-title":"BioMed Microdevices"},{"key":"B65","article-title":"Antibodies to cholesterol, cholesterol conjugates and liposomes: implications for atherosclerosis and autoimmunity","volume":"10","author":"Alving","year":"1991","journal-title":"Crit Rev Immunol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1080\/08982100802309552","article-title":"Liposome-mediated triggering of complement cascade","volume":"18","author":"Moghimi","year":"2008","journal-title":"J Liposome Res"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.94.19.10356","article-title":"The epitopes for some antiphospholipid antibodies are adducts of oxidized phospholipid and beta2 glycoprotein 1 (and other proteins)","volume":"94","author":"Horkko","year":"1997","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.74.12.5672","article-title":"Interactions of C-reactive protein and complement with liposomes","volume":"74","author":"Richards","year":"1977","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1038\/281155a0","article-title":"Interaction of C-reactive protein with artificial phosphatidylcholine bilayers","volume":"281","author":"Volanakis","year":"1979","journal-title":"Nature"},{"key":"B70","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.128.3.1302","article-title":"Antibody restores human alternative complement pathway activation by mouse erythrocytes rendered functionally deficient by pretreatment with pronase","volume":"128","author":"Moore","year":"1982","journal-title":"J Immunol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1021\/acs.nanolett.0c01011","article-title":"Overcoming Nanoparticle-Mediated Complement Activation by Surface PEG Pairing","volume":"20","author":"Pannuzzo","year":"2020","journal-title":"Nano Lett"},{"key":"B72","first-page":"283","article-title":"Long-circulating and target-specific nanoparticles: theory to practice","volume":"53","author":"Moghimi","year":"2001","journal-title":"Pharmacol Rev"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2007.10.005","article-title":"Complement activation on surfaces carrying amino groups","volume":"29","author":"Toda","year":"2008","journal-title":"Biomaterials"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2009.01.005","article-title":"Immunocompatibility properties of lipid-polymer hybrid nanoparticles with heterogeneous surface functional groups","volume":"30","author":"Salvador-Morales","year":"2009","journal-title":"Biomaterials"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/0161-5890(88)90064-8","article-title":"The ability of Sephadex to activate human complement is suppressed in specifically substituted functional Sephadex derivatives","volume":"25","author":"Carreno","year":"1988","journal-title":"Mol Immunol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00418","article-title":"Activation of Human Complement System by Dextran-Coated Iron Oxide Nanoparticles Is Not Affected by Dextran\/Fe Ratio, Hydroxyl Modifications, and Crosslinking","volume":"7","author":"Wang","year":"2016","journal-title":"Front Immunol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1021\/mp200375x","article-title":"Different effect of hydrogelation on antifouling and circulation properties of dextran-iron oxide nanoparticles","volume":"9","author":"Karmali","year":"2012","journal-title":"Mol Pharm"},{"key":"B78","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1002\/smll.200801789","article-title":"Systematic surface engineering of magnetic nanoworms for in vivo tumor targeting","volume":"5","author":"Park","year":"2009","journal-title":"Small"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2009.03.056","article-title":"Differential proteomics analysis of the surface heterogeneity of dextran iron oxide nanoparticles and the implications for their in vivo clearance","volume":"30","author":"Simberg","year":"2009","journal-title":"Biomaterials"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1002\/adma.200800004","article-title":"Magnetic Iron Oxide Nanoworms for Tumor Targeting and Imaging","volume":"20","author":"Park","year":"2008","journal-title":"Adv Mater"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.3109\/08982100009031112","article-title":"The Role of Complement Activation in Hypersensitivity to Pegylated Liposomal Doxorubicin (Doxil\u00ae)","volume":"10","author":"Szebeni","year":"2000","journal-title":"J Liposome Res"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2007.05.015","article-title":"PEGylated liposomes elicit an anti-PEG IgM response in a T cell-independent manner","volume":"122","author":"Ishida","year":"2007","journal-title":"J Control Release"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2007.02.010","article-title":"Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes","volume":"119","author":"Wang","year":"2007","journal-title":"J Control Release"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.119.258012","article-title":"The Interplay Between Blood Proteins, Complement, and Macrophages on Nanomedicine Performance and Responses","volume":"370","author":"Moghimi","year":"2019","journal-title":"J Pharmacol Exp Ther"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2011.06.017","article-title":"Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention","volume":"63","author":"Szebeni","year":"2011","journal-title":"Adv Drug Deliver Rev"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/j.tox.2005.07.023","article-title":"Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity","volume":"216","author":"Szebeni","year":"2005","journal-title":"Toxicology"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1166\/jnn.2010.1738","article-title":"Influence of polyethyleneglycol modification on phagocytic uptake of polymeric nanoparticles mediated by immunoglobulin G and complement activation","volume":"10","author":"Yang","year":"2010","journal-title":"J Nanosci Nanotechnol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1016\/0304-4157(92)90038-C","article-title":"Sterically stabilized liposomes","volume":"1113","author":"Woodle","year":"1992","journal-title":"Biochim Biophys Acta"},{"key":"B89","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s00280-007-0525-5","article-title":"An open-label study to evaluate dose and cycle dependence of the pharmacokinetics of pegylated liposomal doxorubicin","volume":"61","author":"Gabizon","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2014.06.038","article-title":"Complement activation-related pseudoallergy: a stress reaction in blood triggered by nanomedicines and biologicals","volume":"61","author":"Szebeni","year":"2014","journal-title":"Mol Immunol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2007.11.049","article-title":"The role of complement in the success of vaccination with conjugated vs. unconjugated polysaccharide antigen","volume":"26","author":"Salehen","year":"2008","journal-title":"Vaccine"},{"key":"B92","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/imr.12802","article-title":"Complement in malaria immunity and vaccines","volume":"293","author":"Kurtovic","year":"2020","journal-title":"Immunol Rev"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00969-18","article-title":"Complement C3 Plays a Key Role in Inducing Humoral and Cellular Immune Responses to Influenza Virus Strain-Specific Hemagglutinin-Based or Cross-Protective M2 Extracellular Domain-Based Vaccination","volume":"92","author":"Kim","year":"2018","journal-title":"J Virol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20090209","article-title":"Visualizing B cell capture of cognate antigen from follicular dendritic cells","volume":"206","author":"Suzuki","year":"2009","journal-title":"J Exp Med"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2008.02.001","article-title":"Locally produced complement fragments C5a and C3a provide both costimulatory and survival signals to naive CD4+ T cells","volume":"28","author":"Strainic","year":"2008","journal-title":"Immunity"},{"key":"B96","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.immuni.2012.08.002","article-title":"Regulation of humoral immunity by complement","volume":"37","author":"Carroll","year":"2012","journal-title":"Immunity"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1126\/science.271.5247.348","article-title":"C3d of complement as a molecular adjuvant: bridging innate and acquired immunity","volume":"271","author":"Dempsey","year":"1996","journal-title":"Science"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1332","article-title":"Exploiting lymphatic transport and complement activation in nanoparticle vaccines","volume":"25","author":"Reddy","year":"2007","journal-title":"Nat Biotechnol"},{"key":"B99","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1146\/annurev.immunol.18.1.393","article-title":"Regulation of B lymphocyte responses to foreign and self-antigens by the CD19\/CD21 complex","volume":"18","author":"Fearon","year":"2000","journal-title":"Annu Rev Immunol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2009.04.002","article-title":"Is complement good or bad for cancer patients","volume":"30","author":"Markiewski","year":"2009","journal-title":"A New Perspect an old dilemma Trends Immunol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2016.03.003","article-title":"Cytotoxic mechanisms of immunotherapy: Harnessing complement in the action of anti-tumor monoclonal antibodies, Semin","volume":"28","author":"Taylor","year":"2016","journal-title":"Immunology"},{"key":"B102","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/nri.2017.97","article-title":"Complement in cancer: untangling an intricate relationship","volume":"18","author":"Reis","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1655","article-title":"Modulation of the antitumor immune response by complement","volume":"9","author":"Markiewski","year":"2008","journal-title":"Nat Immunol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3581","article-title":"History of myeloid-derived suppressor cells","volume":"13","author":"Talmadge","year":"2013","journal-title":"Nat Rev Cancer"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1203487","article-title":"Complement in immune and inflammatory disorders: pathophysiological mechanisms","volume":"190","author":"Ricklin","year":"2013","journal-title":"J Immunol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1201654","article-title":"Anaphylatoxin C5a creates a favorable microenvironment for lung cancer progression","volume":"189","author":"Corrales","year":"2012","journal-title":"J Immunol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-0157","article-title":"Complement c5a receptor facilitates cancer metastasis by altering T-cell responses in the metastatic niche","volume":"74","author":"Vadrevu","year":"2014","journal-title":"Cancer Res"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2012.01.011","article-title":"Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression, Semin","volume":"22","author":"Ostrand-Rosenberg","year":"2012","journal-title":"Cancer Biol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1602057","article-title":"The Ribosomal Protein S19 Suppresses Antitumor Immune Responses via the Complement C5a Receptor 1","volume":"198","author":"Markiewski","year":"2017","journal-title":"J Immunol"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0707332","article-title":"Function, structure and therapeutic potential of complement C5a receptors","volume":"152","author":"Monk","year":"2007","journal-title":"Br J Pharmacol"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1038\/nature04753","article-title":"Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells","volume":"441","author":"Bettelli","year":"2006","journal-title":"Nature"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.01.004","article-title":"PTX3 is an extrinsic oncosuppressor regulating complement-dependent inflammation in cancer","volume":"160","author":"Bonavita","year":"2015","journal-title":"Cell"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-15-1412","article-title":"Autocrine Complement Inhibits IL10-Dependent T-cell-Mediated Antitumor Immunity to Promote Tumor Progression","volume":"6","author":"Wang","year":"2016","journal-title":"Cancer Discovery"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1401401","article-title":"Monitoring and cell-specific deletion of C5aR1 using a novel floxed GFP-C5aR1 reporter knock-in mouse","volume":"194","author":"Karsten","year":"2015","journal-title":"J Immunol"},{"key":"B115","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1593\/neo.121262","article-title":"Genetic and pharmacologic inhibition of complement impairs endothelial cell function and ablates ovarian cancer neovascularization","volume":"14","author":"Nunez-Cruz","year":"2012","journal-title":"Neoplasia"},{"key":"B116","doi-asserted-by":"publisher","first-page":"10346","DOI":"10.1038\/ncomms10346","article-title":"C1q acts in the tumour microenvironment as a cancer-promoting factor independently of complement activation","volume":"7","author":"Bulla","year":"2016","journal-title":"Nat Commun"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2000511","article-title":"Complement as Prognostic Biomarker and Potential Therapeutic Target in Renal Cell Carcinoma","volume":"205","author":"Reese","year":"2020","journal-title":"J Immunol"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0891","article-title":"Tumor Cells Hijack Macrophage-Produced Complement C1q to Promote Tumor Growth","volume":"7","author":"Roumenina","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2014.02.014","article-title":"Autocrine effects of tumor-derived complement","volume":"6","author":"Cho","year":"2014","journal-title":"Cell Rep"},{"key":"B120","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.smim.2018.02.003","article-title":"Targeting complement-mediated immunoregulation for cancer immunotherapy, Semin","volume":"37","author":"Kolev","year":"2018","journal-title":"Immunology"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1403215","article-title":"Pulmonary alveolar macrophages contribute to the premetastatic niche by suppressing antitumor T cell responses in the lungs","volume":"194","author":"Sharma","year":"2015","journal-title":"J Immunol"},{"key":"B122","doi-asserted-by":"publisher","first-page":"990","DOI":"10.4049\/jimmunol.1901208","article-title":"Therapeutic Targeting of Vasculature in the Premetastatic and Metastatic Niches Reduces Lung Metastasis","volume":"204","author":"Ghouse","year":"2020","journal-title":"J Immunol"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1111\/j.1582-4934.2008.00350.x","article-title":"The alternative complement pathway revisited","volume":"12","author":"Harboe","year":"2008","journal-title":"J Cell Mol Med"},{"key":"B124","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.jconrel.2014.03.051","article-title":"Cancer nanomedicine and the complement system activation paradigm: Anaphylaxis and tumour growth","volume":"190","author":"Moghimi","year":"2014","journal-title":"J Controlled Release Off J Controlled Release Soc"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1016\/j.nano.2014.08.010","article-title":"Liposome promotion of tumor growth is associated with angiogenesis and inhibition of antitumor immune responses","volume":"11","author":"Sabnani","year":"2014","journal-title":"Nanomed Nanotechnol Biol Med"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2009.02.014","article-title":"Complement-mediated tumour growth: implications for cancer nanotechnology and nanomedicines","volume":"46","author":"Moghimi","year":"2009","journal-title":"Mol Immunol"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2017.12.023","article-title":"Liposome-induced immunosuppression and tumor growth is mediated by macrophages and mitigated by liposome-encapsulated alendronate","volume":"271","author":"Rajan","year":"2018","journal-title":"J Controlled Release Off J Controlled Release Soc"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1016\/j.nano.2014.04.011","article-title":"Just so stories: The random acts of anti-cancer nanomedicine performance","volume":"10","author":"Moghimi","year":"2014","journal-title":"Nanomed Nanotechnol Biol Med"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2011.09.063","article-title":"Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress","volume":"161","author":"Lammers","year":"2012","journal-title":"J Controlled Release Off J Controlled Release Soc"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2016.04.028","article-title":"Meta-analysis of clinical and preclinical studies comparing the anticancer efficacy of liposomal versus conventional non-liposomal doxorubicin","volume":"232","author":"Petersen","year":"2016","journal-title":"J Controlled Release Off J Controlled Release Soc"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1038\/35077246","article-title":"Progress in human tumour immunology and immunotherapy","volume":"411","author":"Rosenberg","year":"2001","journal-title":"Nature"},{"key":"B132","doi-asserted-by":"publisher","first-page":"h1831","DOI":"10.1136\/bmj.h1831","article-title":"Experimental drug that injured UK volunteers resumes in human trials","volume":"350","author":"Dyer","year":"2015","journal-title":"BMJ"},{"key":"B133","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1111\/bcp.12165","article-title":"Severity of the TGN1412 trial disaster cytokine storm correlated with IL-2 release","volume":"76","author":"Eastwood","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2013.12.009","article-title":"Cytokine release assays: current practices and future directions","volume":"66","author":"Finco","year":"2014","journal-title":"Cytokine"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12605","article-title":"The return of the prodigal son and the extraordinary development route of antibody TGN1412 - lessons for drug development and clinical pharmacology","volume":"79","author":"Kenter","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12096","article-title":"Giving monoclonal antibodies to healthy volunteers in phase 1 trials: is it safe","volume":"76","author":"Tranter","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"B137","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jim.2015.04.020","article-title":"Cytokine release assays for the prediction of therapeutic mAb safety in first-in man trials - Whole blood cytokine release assays are poorly predictive for TGN1412 cytokine storm","volume":"424","author":"Vessillier","year":"2015","journal-title":"J Immunol Methods"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1172\/JCI66895","article-title":"Nanoparticle clearance is governed by Th1\/Th2 immunity and strain background","volume":"123","author":"Jones","year":"2013","journal-title":"J Clin Invest"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2013-0126","article-title":"The role of pegylated liposomal doxorubicin in ovarian cancer: a meta-analysis of randomized clinical trials","volume":"18","author":"Gibson","year":"2013","journal-title":"Oncologist"},{"key":"B140","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.drup.2016.10.003","article-title":"New insights and evolving role of pegylated liposomal doxorubicin in cancer therapy","volume":"29","author":"Gabizon","year":"2016","journal-title":"Drug Resist Update"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.491","article-title":"Pegylated liposomal mitomycin C prodrug enhances tolerance of mitomycin C: a phase 1 study in advanced solid tumor patients","volume":"4","author":"Golan","year":"2015","journal-title":"Cancer Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2020.603039\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T02:01:22Z","timestamp":1697508082000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2020.603039\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,8]]},"references-count":141,"alternative-id":["10.3389\/fimmu.2020.603039"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.603039","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,8]]},"article-number":"603039"}}